Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

6 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

    Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NV7xOY97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3TbIVKSzVyPUCuNFAxOjh5IN88US=> NGjxdYlUSU6JRWK=
LC-2-ad MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLZeotKSzVyPUCuNFAxOzF5IN88US=> NYPpWlZYW0GQR1XS
RL95-2 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX2TWM2OD1yLkCwNFY3QCEQvF2= NXzlXlM4W0GQR1XS
MZ1-PC MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMECwO|I6KM7:TR?= MVrTRW5ITVJ?
TE-8 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPWR21pUUN3ME2wMlAxOTF5IN88US=> MljHV2FPT0WU
SW954 M4PkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm3VGZKSzVyPUCuNFAyOTlizszN NXLhbmNCW0GQR1XS
TE-11 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ZZWlEPTB;MD6wNFEzOyEQvF2= MX7TRW5ITVJ?
PSN1 MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KwT2lEPTB;MD6wNFE{KM7:TR?= MnfHV2FPT0WU
MOLT-4 NV3PN2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XHPWlEPTB;MD6wNFE1QSEQvF2= MWjTRW5ITVJ?
697 NIXIVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT6PVgzUUN3ME2wMlAxOTVizszN M3T0SHNCVkeHUh?=
ETK-1 NHnLXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFq0eXVKSzVyPUCuNFAyPTJizszN M4mxU3NCVkeHUh?=
TE-10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3aTWM2OD1yLkCwNVU1KM7:TR?= MnzsV2FPT0WU
HUTU-80 NYf3[HZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3YTWM2OD1yLkCwNVY5KM7:TR?= MormV2FPT0WU
NTERA-S-cl-D1 NEnxVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XZXmlEPTB;MD6wNFIxQSEQvF2= M1HiZnNCVkeHUh?=
MFH-ino NVfBNIV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[4W2NKSzVyPUCuNFAzPjhizszN MUjTRW5ITVJ?
IA-LM M1jVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID4bmdKSzVyPUCuNFAzQCEQvF2= MlTYV2FPT0WU
MC116 NHe4N3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{izOWlEPTB;MD6wNFI5QSEQvF2= MYfTRW5ITVJ?
RKO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfzbYtKUUN3ME2wMlAxOjl6IN88US=> NV\5RVZzW0GQR1XS
MRK-nu-1 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMECyPVkh|ryP Mn72V2FPT0WU
VA-ES-BJ NVLxWpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMECzJO69VQ>? M4jacHNCVkeHUh?=
KALS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD1yLkCwN|A5KM7:TR?= Mn[5V2FPT0WU
BB30-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzqVJA2UUN3ME2wMlAxOzF2IN88US=> MmjQV2FPT0WU
ACN NHG0OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMECzNVYh|ryP NWXTbo93W0GQR1XS
TE-9 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMECzNlYh|ryP NYHBeY1JW0GQR1XS
SIG-M5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMECzNlch|ryP MWTTRW5ITVJ?
no-10 NYq5VXV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjKVZpuUUN3ME2wMlAxOzZ{IN88US=> NUnh[G1bW0GQR1XS
EW-1 NWHDVox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMECzO|Eh|ryP NEG2O5RUSU6JRWK=
SK-LMS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7SWJE4UUN3ME2wMlAxPDBzIN88US=> M{LuXnNCVkeHUh?=
GT3TKB MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRcXBKSzVyPUCuNFA1OzRizszN NGnqUXRUSU6JRWK=
ES4 NIDme2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTtTWM2OD1yLkCwOFQ6KM7:TR?= NHfZXHNUSU6JRWK=
IMR-5 M1fVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[welJXUUN3ME2wMlAxPDVizszN NW\2[GtlW0GQR1XS
NCI-H1648 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT3TWM2OD1yLkCwOFY6KM7:TR?= M4q5W3NCVkeHUh?=
MV-4-11 NIT4VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z0bWlEPTB;MD6wNFQ4PSEQvF2= MYXTRW5ITVJ?
SK-UT-1 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTtTWM2OD1yLkCwOFgh|ryP NVvpb5JwW0GQR1XS
NB13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\CTWM2OD1yLkCwOFkyKM7:TR?= NWe0RWc6W0GQR1XS
DJM-1 M3;TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvJOWlKSzVyPUCuNFA2OyEQvF2= NU\xT2VmW0GQR1XS
ES8 NVzPb|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonITWM2OD1yLkCwOVM5KM7:TR?= MYjTRW5ITVJ?
TE-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rWXWlEPTB;MD6wNFU4KM7:TR?= Ml3tV2FPT0WU
KS-1 NGPKNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEC1PFIh|ryP MlXGV2FPT0WU
TE-1 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC2NFYh|ryP MXHTRW5ITVJ?
ATN-1 NF[4SFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G0WmlEPTB;MD6wNFYxQSEQvF2= M4jI[3NCVkeHUh?=
A4-Fuk NH\yU|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7WbFRlUUN3ME2wMlAxPjFzIN88US=> M2rzSHNCVkeHUh?=
ALL-PO MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjyemRKSzVyPUCuNFA3OyEQvF2= NXfReXY5W0GQR1XS
BE-13 M1PwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2ySY1FUUN3ME2wMlAxPjN4IN88US=> MkXMV2FPT0WU
KM12 NELRW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1cIxZUUN3ME2wMlAxPjN5IN88US=> MoC3V2FPT0WU
NOS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nlWWlEPTB;MD6wNFY2KM7:TR?= MVPTRW5ITVJ?
SW962 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;UT2lEPTB;MD6wNFY3OiEQvF2= NFL6bJlUSU6JRWK=
OCUB-M NFTmSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rO[2lEPTB;MD6wNFY3OiEQvF2= M2rVXXNCVkeHUh?=
NCI-H510A NFLjPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Rb4hHUUN3ME2wMlAxPjZ3IN88US=> M3v0T3NCVkeHUh?=
EW-16 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jHfGlEPTB;MD6wNFY6PCEQvF2= M4TQUHNCVkeHUh?=
KGN MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP6RYdKSzVyPUCuNFA4OTJizszN MUnTRW5ITVJ?
LS-411N NFLDe|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEC3NVch|ryP Mkf6V2FPT0WU
Becker NWHOO2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMEC3NkDPxE1? Mm\0V2FPT0WU
HC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6zTWM2OD1yLkCwO|IyKM7:TR?= NGXrbplUSU6JRWK=
CESS M1LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLIVodrUUN3ME2wMlAxPzN5IN88US=> MYLTRW5ITVJ?
KURAMOCHI NUT1OnYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PzPGlEPTB;MD6wNFc1QCEQvF2= NVG4eGNPW0GQR1XS
TGBC24TKB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLhTWM2OD1yLkCwO|UzKM7:TR?= NG\pSHJUSU6JRWK=
SW982 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn1WHhKSzVyPUCuNFA4PjZizszN NF\MW3JUSU6JRWK=
HCE-4 M1i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLkdFlKSzVyPUCuNFA4PjdizszN M3\vbHNCVkeHUh?=
LOUCY NXW2bVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojsTWM2OD1yLkCwO|c2KM7:TR?= M4HH[HNCVkeHUh?=
8-MG-BA NY\4W2RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP6fIFmUUN3ME2wMlAxPzl4IN88US=> NG\MNGhUSU6JRWK=
HT-144 NXHHOFJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljoTWM2OD1yLkCwPEDPxE1? MUjTRW5ITVJ?
LXF-289 NXzGVYlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrMTWM2OD1yLkCwPFE5KM7:TR?= M4qzR3NCVkeHUh?=
RS4-11 NXy5d5c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrsb3BKSzVyPUCuNFA5OzZizszN MnjtV2FPT0WU
DEL NXjBOJBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmxRWpSUUN3ME2wMlAxQDR3IN88US=> NXXwdJhYW0GQR1XS
OCI-AML2 NHq5eZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHtN49nUUN3ME2wMlAxQDV{IN88US=> NVHLPVZyW0GQR1XS
CCRF-CEM NUPvNlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMEC4O|Eh|ryP NXj1SIY3W0GQR1XS
A388 NX3tU|NwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jxcGlEPTB;MD6wNFg4PCEQvF2= NFT1UVhUSU6JRWK=
KNS-42 M2C5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEmy[HpKSzVyPUCuNFA5QTFizszN M{jiRXNCVkeHUh?=
OVCAR-4 NXri[XZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7lTVVKSzVyPUCuNFA6ODRizszN NWGyc49LW0GQR1XS
NCI-H1355 NF3ke2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\2eGlEPTB;MD6wNFkyPCEQvF2= NH7NNG5USU6JRWK=
BL-70 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPwXplYUUN3ME2wMlAxQTNizszN NXP0TJJjW0GQR1XS
BL-41 NFTHRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO4TWM2OD1yLkCwPVM1KM7:TR?= NYLqVGxHW0GQR1XS
A101D MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfPTWM2OD1yLkCwPVYh|ryP MkfxV2FPT0WU
HL-60 M3Ppemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C5W2lEPTB;MD6wNFk3PiEQvF2= MX;TRW5ITVJ?
COR-L279 NYDoSYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEC5PVkh|ryP MofkV2FPT0WU
NCI-SNU-16 M1fzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkThTWM2OD1yLkCxNFA5KM7:TR?= MnO2V2FPT0WU
Calu-6 M1;sTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTH[JBWUUN3ME2wMlAyODF{IN88US=> NWCxWod1W0GQR1XS
SR NWn1b5FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TxZ2lEPTB;MD6wNVAzPiEQvF2= M4r0SXNCVkeHUh?=
QIMR-WIL M{LhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEGwN|Mh|ryP MXXTRW5ITVJ?
LB647-SCLC NEDV[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TncGlEPTB;MD6wNVA2OSEQvF2= MmHWV2FPT0WU
RPMI-8226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXCbWRmUUN3ME2wMlAyOTB{IN88US=> Mn\sV2FPT0WU
SK-PN-DW M3rxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEGxNVIh|ryP MVjTRW5ITVJ?
SF268 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEGxOVEh|ryP NYHwU5pZW0GQR1XS
HD-MY-Z NIrYdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXLPHFmUUN3ME2wMlAyOTZ|IN88US=> MX7TRW5ITVJ?
DOHH-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZW2lEPTB;MD6wNVIxOyEQvF2= M4rheHNCVkeHUh?=
SCC-3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LZR2lEPTB;MD6wNVIxPCEQvF2= NF3LNHFUSU6JRWK=
ST486 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLZTWM2OD1yLkCxNlA1KM7:TR?= NVu4d5d[W0GQR1XS
NALM-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0fWZKSzVyPUCuNFEzOTRizszN M1zUeXNCVkeHUh?=
NCI-H1436 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH3S2dKSzVyPUCuNFEzOzFizszN M1nEO3NCVkeHUh?=
KE-37 M4f6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK0SZlYUUN3ME2wMlAyOjN2IN88US=> NYWxR5IxW0GQR1XS
RPMI-8402 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rMVmlEPTB;MD6wNVI2PiEQvF2= MmGwV2FPT0WU
RXF393 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfPNZI3UUN3ME2wMlAyOjV5IN88US=> MofCV2FPT0WU
KARPAS-45 M4G1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jlfWlEPTB;MD6wNVI4KM7:TR?= NWTBWVdvW0GQR1XS
HOP-62 NI\PRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEGyO|Yh|ryP MnTpV2FPT0WU
ES1 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;YS5R4UUN3ME2wMlAyOjh6IN88US=> NETEdo1USU6JRWK=
L-363 Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L4VmlEPTB;MD6wNVM2OSEQvF2= NIHCRWpUSU6JRWK=
GI-1 NYLiZlFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjTTWM2OD1yLkCxN|c{KM7:TR?= MYTTRW5ITVJ?
CTV-1 NWP0U25kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEG0O|gh|ryP MWrTRW5ITVJ?
TE-5 NEPBZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rkc2lEPTB;MD6wNVQ6PiEQvF2= NEnNbIVUSU6JRWK=
SNU-C2B MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHPTWM2OD1yLkCxOFk3KM7:TR?= NUC3[VQ3W0GQR1XS
K-562 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorZTWM2OD1yLkCxOVE3KM7:TR?= NWPFdFBLW0GQR1XS
SNB75 NGPIPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn0TmFKSzVyPUCuNFE2PCEQvF2= NH20T3FUSU6JRWK=
MOLT-13 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEG2N|ch|ryP NWG5dVhSW0GQR1XS
LS-123 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[4VGlEPTB;MD6wNVY3PCEQvF2= NVLmSZpuW0GQR1XS
NCI-SNU-5 M2TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDFfFA5UUN3ME2wMlAyPzBzIN88US=> M4n2V3NCVkeHUh?=
Daudi MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEG3NFgh|ryP MVfTRW5ITVJ?
A253 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fh[GlEPTB;MD6wNVc{QCEQvF2= M2XWTnNCVkeHUh?=
TGBC1TKB NIjsXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHaeGxKSzVyPUCuNFE4PTJizszN NXvEcYtxW0GQR1XS
SJSA-1 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC2Z4o{UUN3ME2wMlAyPzZ5IN88US=> MojqV2FPT0WU
NCCIT MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEG3Olkh|ryP MVHTRW5ITVJ?
NCI-H69 NF;YcIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3ydYhKSzVyPUCuNFE4PzhizszN MUPTRW5ITVJ?
SH-4 NILEdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEG4PVUh|ryP Ml30V2FPT0WU
HCC1187 M3fybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLy[opFUUN3ME2wMlAyQTJ2IN88US=> MoD0V2FPT0WU
HCC1599 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEKwNkDPxE1? NEDEZWFUSU6JRWK=
ONS-76 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rzOGlEPTB;MD6wNlA{PiEQvF2= NU[weVJSW0GQR1XS
KU812 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXiWotlUUN3ME2wMlAzODN7IN88US=> MWDTRW5ITVJ?
ML-2 NFXKboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjGTWM2OD1yLkCyNFQ4KM7:TR?= Mo\IV2FPT0WU
HCE-T NX6we4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrmRW9EUUN3ME2wMlAzODl{IN88US=> M{nDbHNCVkeHUh?=
NCI-H446 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEKxNVIh|ryP MonLV2FPT0WU
RPMI-6666 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\sUWQ6UUN3ME2wMlAzOTR7IN88US=> MVfTRW5ITVJ?
MOLT-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PZbmlEPTB;MD6wNlE2OyEQvF2= MVXTRW5ITVJ?
JiyoyeP-2003 NIXOSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDNZ5NKSzVyPUCuNFIyPzZizszN MnXhV2FPT0WU
MHH-PREB-1 NYLScWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPtRpBkUUN3ME2wMlAzOTlzIN88US=> Mn\EV2FPT0WU
MC-CAR M2DXWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZTWM2OD1yLkCyN|I3KM7:TR?= Mn3aV2FPT0WU
BC-3 M{nPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDvfoQzUUN3ME2wMlAzOzR2IN88US=> NYjpVlRXW0GQR1XS
KINGS-1 MkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXvTWM2OD1yLkCyN|U2KM7:TR?= M4PtZXNCVkeHUh?=
PF-382 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTJPFFkUUN3ME2wMlAzOzd6IN88US=> MmLyV2FPT0WU
J-RT3-T3-5 NVPrNFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEKzPFMh|ryP MoHFV2FPT0WU
SF539 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ETWM2OD1yLkCyOFAyKM7:TR?= MW\TRW5ITVJ?
LB831-BLC M3T1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC2TWM2OD1yLkCyOFg2KM7:TR?= NYG3PHpOW0GQR1XS
DMS-114 NI\ne3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fl[GlEPTB;MD6wNlUxOiEQvF2= NGDhXmRUSU6JRWK=
LB1047-RCC M1fqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG1SWJKSzVyPUCuNFI2OSEQvF2= M{Xsb3NCVkeHUh?=
LB771-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHYWGpKSzVyPUCuNFI2OzRizszN NUm1fHk6W0GQR1XS
BB65-RCC M3qyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEK1N|Qh|ryP MYXTRW5ITVJ?
BV-173 NGT1[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyb2pKSzVyPUCuNFI2PTRizszN MYPTRW5ITVJ?
ARH-77 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfMd2lKSzVyPUCuNFI3ODFizszN Mln3V2FPT0WU
IST-MEL1 NHH2[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;xTWM2OD1yLkCyOlI{KM7:TR?= NH7yTIFUSU6JRWK=
NB1 NWfIcYRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEK2PFch|ryP MXvTRW5ITVJ?
EoL-1-cell NIjLTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjSbWV3UUN3ME2wMlAzPjh6IN88US=> MUTTRW5ITVJ?
KY821 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPPeZdKSzVyPUCuNFI3QTdizszN MVjTRW5ITVJ?
CMK NF7wTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7SNm9KSzVyPUCuNFI4OzRizszN NIT6TWxUSU6JRWK=
NCI-H2126 MkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEK3Olgh|ryP MXPTRW5ITVJ?
NCI-H526 NWn2b2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonRTWM2OD1yLkCyPFkyKM7:TR?= NEn3clhUSU6JRWK=
COLO-684 NULodYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPwWnRZUUN3ME2wMlAzQTB6IN88US=> MnTiV2FPT0WU
NCI-H747 M3HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHTTWM2OD1yLkCyPVM{KM7:TR?= MmHDV2FPT0WU
JAR MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYXGFKSzVyPUCuNFI6PDZizszN NFW0RldUSU6JRWK=
MEG-01 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3flSGlEPTB;MD6wNlk4QCEQvF2= M4nYb3NCVkeHUh?=
MONO-MAC-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEOwNlMh|ryP M3nVXHNCVkeHUh?=
IST-SL1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e2bWlEPTB;MD6wN|A1OiEQvF2= MYLTRW5ITVJ?
CPC-N MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEOwO|kh|ryP M{fnNHNCVkeHUh?=
NCI-H1963 NVSzXldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f5XGlEPTB;MD6wN|E{OSEQvF2= NIPnd41USU6JRWK=
K052 M1raXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z2W2lEPTB;MD6wN|I1PyEQvF2= NHHTe5NUSU6JRWK=
KM-H2 M4f2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe2[FlKSzVyPUCuNFM{ODdizszN NIjGTYdUSU6JRWK=
TE-12 M1Li[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxTWM2OD1yLkCzN|A6KM7:TR?= NV3XWmV7W0GQR1XS
TK10 NUHsRYwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0eppKSzVyPUCuNFM{PTZizszN NGnmTVVUSU6JRWK=
NMC-G1 M3XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHQTWM2OD1yLkCzOFUzKM7:TR?= NFj6RZpUSU6JRWK=
no-11 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TOdmlEPTB;MD6wN|Q4QCEQvF2= NVLQRXpxW0GQR1XS
NCI-H524 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OwdGlEPTB;MD6wN|UzQSEQvF2= NGToSVRUSU6JRWK=
MHH-CALL-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD1eFNnUUN3ME2wMlA{PTZ{IN88US=> Mn7TV2FPT0WU
GB-1 M2[4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Wyd2lEPTB;MD6wN|Yh|ryP NGrOcGZUSU6JRWK=
OPM-2 MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO1TWM2OD1yLkCzOlc{KM7:TR?= M3\Le3NCVkeHUh?=
RH-1 M123b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\YS3dJUUN3ME2wMlA{QDF7IN88US=> NGLLSHFUSU6JRWK=
NCI-H64 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW2TWM2OD1yLkCzPFU4KM7:TR?= NEHFN49USU6JRWK=
EVSA-T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3JNFJKSzVyPUCuNFM6OjNizszN NFrzOoFUSU6JRWK=
KARPAS-299 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjSSFJlUUN3ME2wMlA{QThizszN Mn:3V2FPT0WU
MZ7-mel NVzFeVVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETwVG9KSzVyPUCuNFQxPCEQvF2= MWTTRW5ITVJ?
LB373-MEL-D MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X2bmlEPTB;MD6wOFExPSEQvF2= NH3G[npUSU6JRWK=
HEL NVTTWVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLhbXJKSzVyPUCuNFQyPCEQvF2= MlTVV2FPT0WU
SW872 NU[5cmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHFc|hiUUN3ME2wMlA1OjFizszN NUHHWJJFW0GQR1XS
DU-4475 NXr1V|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMESyOFQh|ryP NIfyNlJUSU6JRWK=
IST-SL2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nscGlEPTB;MD6wOFI4PSEQvF2= M3viRnNCVkeHUh?=
NCI-H82 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjETWM2OD1yLkC0N|A4KM7:TR?= MlvoV2FPT0WU
LC4-1 M1[1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwMESzOVEh|ryP NESwTYlUSU6JRWK=
HDLM-2 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1THeGlEPTB;MD6wOFM6OiEQvF2= Mn24V2FPT0WU
MMAC-SF Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7Pemk5UUN3ME2wMlA1PTN2IN88US=> NFu1[lVUSU6JRWK=
L-540 NYXmOmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMES2N|kh|ryP M{DxN3NCVkeHUh?=
MZ2-MEL MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LPfWlEPTB;MD6wOFc1OiEQvF2= Mlv3V2FPT0WU
LU-134-A M2jiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOweYpkUUN3ME2wMlA1Pzd|IN88US=> MYrTRW5ITVJ?
UACC-257 NHHVUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnweHJKSzVyPUCuNFQ5PDlizszN MlfsV2FPT0WU
NCI-H1581 M2DPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HzNmlEPTB;MD6wOFk2OyEQvF2= MmLJV2FPT0WU
NB17 NFzWb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMES5O|kh|ryP MnP6V2FPT0WU
SBC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPJNoZKSzVyPUCuNFUxPDJizszN MXPTRW5ITVJ?
TALL-1 M2nFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLJfpc2UUN3ME2wMlA2ODR3IN88US=> NHHsNI9USU6JRWK=
NCI-H1304 M2n4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPDUpZKSzVyPUCuNFUzODhizszN M2W3e3NCVkeHUh?=
NEC8 MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HWc2lEPTB;MD6wOVI5PiEQvF2= NVfyXXNGW0GQR1XS
CAL-148 NVLXOpFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TyS2lEPTB;MD6wOVQ{QSEQvF2= MkHTV2FPT0WU
CGTH-W-1 MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj1RVA4UUN3ME2wMlA2PDR7IN88US=> M3PTN3NCVkeHUh?=
NCI-H889 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz3XmhKSzVyPUCuNFU2QTJizszN NH;RbFBUSU6JRWK=
GR-ST MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMEW2NlEh|ryP Mnz0V2FPT0WU
KARPAS-422 NYrpcHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\QVJc6UUN3ME2wMlA2PjVizszN NHnIfXFUSU6JRWK=
RPMI-8866 M2K5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\lTWM2OD1yLkC1O|EzKM7:TR?= MnrQV2FPT0WU
SCLC-21H NWX4Sow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDmRWNKSzVyPUCuNFU5QDRizszN MmrQV2FPT0WU
COR-L88 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjJTWM2OD1yLkC1PVI4KM7:TR?= NIfPRWFUSU6JRWK=
LU-139 M1HWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHYTWM2OD1yLkC1PVg3KM7:TR?= NXq0U3VRW0GQR1XS
SF126 M3TofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPMfodKSzVyPUCuNFYyOzNizszN M3qyUHNCVkeHUh?=
NCI-H1882 M1XSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m4Z2lEPTB;MD6wOlQzPCEQvF2= M{nyXnNCVkeHUh?=
EW-24 NHP2ZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvWTWM2OD1yLkC2OFg{KM7:TR?= MWXTRW5ITVJ?
CP67-MEL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW5ZVdEUUN3ME2wMlA3QDFizszN MoXDV2FPT0WU
DG-75 NYX5bZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\idmhKSzVyPUCuNFY5QTlizszN NUK2fpN[W0GQR1XS
LOXIMVI NX3LbYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qe2lEPTB;MD6wO|AzQCEQvF2= NG\ob45USU6JRWK=
HH NITROoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrwO5RKSzVyPUCuNFcyPTdizszN NGXicXZUSU6JRWK=
K5 NFTOZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvVnY6UUN3ME2wMlA4OjJ4IN88US=> NVjzVXFOW0GQR1XS
EC-GI-10 Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT2TWM2OD1yLkC3NlU4KM7:TR?= NGXJZWFUSU6JRWK=
SK-N-DZ MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWdmlEPTB;MD6wO|MxPyEQvF2= NH7hb5dUSU6JRWK=
A3-KAW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D1UGlEPTB;MD6wO|M2OSEQvF2= NEfHcYZUSU6JRWK=
MLMA NWLmcmVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xk[WlEPTB;MD6wO|Q3PSEQvF2= MWTTRW5ITVJ?
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\odIxwUUN3ME2wMlA4PzB5IN88US=> M1T3V3NCVkeHUh?=
OS-RC-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEe3OFgh|ryP NFXVS3hUSU6JRWK=
CTB-1 M{PoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jKR2lEPTB;MD6wO|gyKM7:TR?= MnfoV2FPT0WU
IST-MES1 NFvMe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXJTWM2OD1yLkC3PVEzKM7:TR?= NF\6SVlUSU6JRWK=
LS-1034 NHLTdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3YZ2I5UUN3ME2wMlA5ODN3IN88US=> MkHuV2FPT0WU
HT M1K1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TV[GlEPTB;MD6wPFA5PiEQvF2= NV;SdINRW0GQR1XS
NCI-H2141 NHPyeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPJTWM2OD1yLkC4NUDPxE1? M4\NVXNCVkeHUh?=
LB2518-MEL NWCzXmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXES3dKSzVyPUCuNFgyPDFizszN Mo\YV2FPT0WU
GI-ME-N NH\NSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfve5FKSzVyPUCuNFg1PTJizszN MUDTRW5ITVJ?
TGW NVnwRYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjWdpFwUUN3ME2wMlA5PjB5IN88US=> NWrqR3czW0GQR1XS
SK-NEP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq5PZVmUUN3ME2wMlA5PjRzIN88US=> NGPxfZlUSU6JRWK=
NOMO-1 NFi1WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEmyO|Uh|ryP NWPoeGVvW0GQR1XS
ES6 NXXPclV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0TIVKSzVyPUCuNFk2QDlizszN M1ThdnNCVkeHUh?=
NCI-H209 M33PVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TyemlEPTB;MD6wPVc5PiEQvF2= NILpcXBUSU6JRWK=
GAK NH20U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPCTWM2OD1yLkGwNVYh|ryP M2\xVXNCVkeHUh?=
BC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUCzOlEh|ryP MmToV2FPT0WU
KLE MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[2TWM2OD1yLkGwOFQ{KM7:TR?= MkTtV2FPT0WU
EW-3 MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUC5PEDPxE1? MmraV2FPT0WU
NKM-1 NG\XVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMUGxJO69VQ>? NFK2V2dUSU6JRWK=
D-336MG M2HHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLs[WhMUUN3ME2wMlEyOjR2IN88US=> MXXTRW5ITVJ?
NB69 M3SzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nZVmlEPTB;MD6xNVMxOSEQvF2= MVTTRW5ITVJ?
D-263MG M2\IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMUG3NVIh|ryP MYPTRW5ITVJ?
KP-N-YS Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jWRmlEPTB;MD6xNlI6OSEQvF2= NYnpNXNQW0GQR1XS
NCI-H1155 NHrQb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInZVIZKSzVyPUCuNVI2PThizszN MYnTRW5ITVJ?
BOKU NV7UcIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly3TWM2OD1yLkGyOVc6KM7:TR?= MnnyV2FPT0WU
LAMA-84 NH;TWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnLTWM2OD1yLkGyPVkh|ryP M1jHeXNCVkeHUh?=
Raji NHznVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUOxNVch|ryP MUTTRW5ITVJ?
LU-65 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nVXmlEPTB;MD6xN|MxPyEQvF2= MVHTRW5ITVJ?
NCI-H187 NE\GUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4mwbmlEPTB;MD6xN|kzPCEQvF2= MXfTRW5ITVJ?
GCIY MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTnTHIzUUN3ME2wMlE1QTBzIN88US=> MkLrV2FPT0WU
NCI-H2107 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3VeXF3UUN3ME2wMlE2ODhizszN NXPpOYhVW0GQR1XS
NCI-H1522 NWLqUYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILCPWhKSzVyPUCuNVUzPjZizszN NFXRXllUSU6JRWK=
NB6 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DaSWlEPTB;MD6xOVYzOyEQvF2= NGHQelRUSU6JRWK=
EM-2 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjOTWM2OD1yLkG1O|A3KM7:TR?= Ml;yV2FPT0WU
HCC2218 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPFTWM2OD1yLkG1PVgh|ryP NELMWmFUSU6JRWK=
NCI-H748 NVuwbG1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISyUpBKSzVyPUCuNVY{PzZizszN M{K5PHNCVkeHUh?=
MS-1 NIezc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{C4[2lEPTB;MD6xOlU{PyEQvF2= Ml3JV2FPT0WU
NB5 NVfRNodET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjw[|hMUUN3ME2wMlE3PTl5IN88US=> MnvHV2FPT0WU
OMC-1 M1rFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPUpJzUUN3ME2wMlE3Pjh6IN88US=> NVfXcXgxW0GQR1XS
NCI-H345 NHGzeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2eppzUUN3ME2wMlE3QTJ6IN88US=> MVvTRW5ITVJ?
L-428 M{j6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jtfmlEPTB;MD6xOlk1PSEQvF2= NX;jUnBuW0GQR1XS
SCH NV7lfYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKeVVLUUN3ME2wMlE5Pjh3IN88US=> MV7TRW5ITVJ?
NCI-H1417 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nhOmlEPTB;MD6xPVIzPyEQvF2= NX6xcFVSW0GQR1XS
COLO-320-HSR NGjGO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMUm1N|Ih|ryP NICyU2JUSU6JRWK=
BT-474 NYTRdY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfTdGhiUUN3ME2wMlIxQDl{IN88US=> M2XIOHNCVkeHUh?=
GDM-1 M2XNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\jTWM2OD1yLkKxPVcyKM7:TR?= MnnlV2FPT0WU
NCI-H2196 NUTFe4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjyTXBKSzVyPUCuNlIzOzVizszN MWPTRW5ITVJ?
KP-N-RT-BM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMkKzOFkh|ryP MWDTRW5ITVJ?
KNS-81-FD MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnSTWM2OD1yLkKyPVU5KM7:TR?= M1TIN3NCVkeHUh?=
COLO-668 M4jYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMkO2O|Uh|ryP Mk\jV2FPT0WU
C2BBe1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vLbmlEPTB;MD6yOlc1PyEQvF2= M{jRVXNCVkeHUh?=
Ramos-2G6-4C10 M1mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn2yTWM2OD1yLkK2PVU1KM7:TR?= M3\6fHNCVkeHUh?=
CAS-1 NEPtNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjuSY5KSzVyPUCuNlcxQTZizszN M2S5ZXNCVkeHUh?=
GOTO NYTUdFFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXzTWM2OD1yLkK3PFk1KM7:TR?= NInaTmZUSU6JRWK=
LP-1 NIHQOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMkiwOVch|ryP MYrTRW5ITVJ?
NCI-SNU-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLMTWM2OD1yLkK5OFIzKM7:TR?= M2TueXNCVkeHUh?=
EB-3 NFW3NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK2TWM2OD1yLkK5PVc6KM7:TR?= M3fafHNCVkeHUh?=
MHH-NB-11 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwM{C0NFIh|ryP NVS3[JRxW0GQR1XS
SK-N-FI NG\ofJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PUXmlEPTB;MD6zNVY6OiEQvF2= M2PHUHNCVkeHUh?=
HCC2157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jFd2lEPTB;MD6zN|kyOyEQvF2= MmfFV2FPT0WU
SIMA Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvhb3JxUUN3ME2wMlM1PThzIN88US=> MYLTRW5ITVJ?
MDA-MB-134-VI NVPoUmpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3iblBZUUN3ME2wMlM3QTJ6IN88US=> NHX4Vo9USU6JRWK=
NCI-H1694 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ENlNJUUN3ME2wMlM4KM7:TR?= MkLUV2FPT0WU
EHEB NF3pU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\scGNHUUN3ME2wMlM6ODh3IN88US=> NV;aWYFHW0GQR1XS
U-266 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSyTWM2OD1yLkO5PFQ3KM7:TR?= MVfTRW5ITVJ?
LC-1F MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3LdXIzUUN3ME2wMlQ{PzZ3IN88US=> NEW4flVUSU6JRWK=
SHP-77 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHEVVFKSzVyPUCuOFc5PTVizszN NUPTdJA5W0GQR1XS
LS-513 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHftRWpKSzVyPUCuOFk{ODdizszN MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID